To evaluate long-term outcomes of active surveillance (AS) applied in low-risk prostate cancer patients, and the impact of re-biopsy results on the prediction of progression.
In our clinic, patients who had undergone AS for low-risk localized prostate cancer between the years 2005-2013 were included in the study.